应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
LLY 礼来
盘前交易 07-22 05:27:13 EDT
857.47
+8.57
+1.01%
盘前
866.52
+9.05
+1.06%
05:26 EDT
最高
880.21
最低
853.00
成交量
378.22万
今开
867.66
昨收
848.90
日振幅
3.21%
总市值
8,149亿
流通市值
8,129亿
总股本
9.50亿
成交额
32.69亿
换手率
0.40%
流通股本
9.48亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
重磅！礼来“减肥针”国内最新获批，司美的最强对手来了？
华尔街见闻 · 07-21 09:30
重磅！礼来“减肥针”国内最新获批，司美的最强对手来了？
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
中国基金报 · 07-20 00:16
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
中国基金报 · 07-20 00:14
减肥药赛道“搅局者”来了，两大巨头“硬碰硬”
司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批
每日经济新闻 · 07-19 22:16
司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批
礼来(LLY)盘前涨超2% 减重适应症获国家药品监督管理局批准
金吾财讯 · 07-19 20:39
礼来(LLY)盘前涨超2% 减重适应症获国家药品监督管理局批准
礼来减肥药在中国获批，将和诺和诺德直接竞争
智通财经 · 07-19 20:30
礼来减肥药在中国获批，将和诺和诺德直接竞争
BUZZ-减肥药在中国获批，礼来公司业绩上升
Reuters · 07-19 20:29
BUZZ-减肥药在中国获批，礼来公司业绩上升
礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争
老虎证券 · 07-19 20:16
礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争
国内“减肥神药”赛道再添一员大将 礼来替尔珀肽减重适应症获批｜快讯
华夏时报 · 07-19 20:12
国内“减肥神药”赛道再添一员大将 礼来替尔珀肽减重适应症获批｜快讯
礼来替尔泊肽获批减重新适应症，GLP-1赛道掀王者之争孰胜孰负？
21世纪经济报道 · 07-19 19:25
礼来替尔泊肽获批减重新适应症，GLP-1赛道掀王者之争孰胜孰负？
礼来(LLY)的穆峰达(替尔泊肽注射液)减重适应症获国家药品监督管理局批准
金吾财讯 · 07-19
礼来(LLY)的穆峰达(替尔泊肽注射液)减重适应症获国家药品监督管理局批准
礼来公司的减肥药替西帕肽在中国获得批准
Reuters · 07-19
礼来公司的减肥药替西帕肽在中国获得批准
最高减重20%！礼来替尔泊肽减重适应证在国内获批，诺和诺德迎强劲对手
澎湃新闻 · 07-19
最高减重20%！礼来替尔泊肽减重适应证在国内获批，诺和诺德迎强劲对手
昨夜今晨 | 道指结束六连涨！特朗普即将发表“新黄金时代”演讲；巴菲特旗下公司盘后涨近48%
老虎资讯综合 · 07-19
昨夜今晨 | 道指结束六连涨！特朗普即将发表“新黄金时代”演讲；巴菲特旗下公司盘后涨近48%
标普500指数扩大跌幅，日内下跌1%。医药板块领跌，礼来（LLY）跌6.2%，诺华（NVS）与雅培（ABT）各跌逾4%
华尔街见闻 · 07-19
标普500指数扩大跌幅，日内下跌1%。医药板块领跌，礼来（LLY）跌6.2%，诺华（NVS）与雅培（ABT）各跌逾4%
BUZZ-礼来股价创逾一个月新低
Reuters · 07-19
BUZZ-礼来股价创逾一个月新低
礼来美股走低
第一财经 · 07-18
礼来美股走低
诺和诺德、礼来均跌超5%！“减肥药双雄”连续两个交易日大跌
老虎资讯综合 · 07-18
诺和诺德、礼来均跌超5%！“减肥药双雄”连续两个交易日大跌
礼来下跌1.3%，报893.86美元/股
金融界 · 07-18
礼来下跌1.3%，报893.86美元/股
礼来跌0.87% 股价跌破900美元大关
自选股智能写手 · 07-18
礼来跌0.87% 股价跌破900美元大关
公司概况
公司名称：
礼来
所属市场：
NYSE
上市日期：
--
主营业务：
礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。
发行价格：
--
{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":857.47,"timestamp":1721419200000,"preClose":848.9,"halted":0,"volume":3782167,"hourTrading":{"tag":"盘前","latestPrice":866.52,"preClose":857.47,"latestTime":"05:26 EDT","volume":177,"amount":153111.8676,"timestamp":1721640372597},"delay":0,"floatShares":948000000,"shares":950405386,"eps":6.79045,"marketStatus":"盘前交易","marketStatusCode":1,"change":8.57,"latestTime":"07-22 05:27:13 EDT","open":867.66,"high":880.21,"low":853,"amount":3268819789.30889,"amplitude":0.032053,"askPrice":868.12,"askSize":6,"bidPrice":866.5,"bidSize":6,"shortable":3,"etf":0,"ttmEps":6.79045,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721655000000},"adr":0,"listingDate":102488400000,"adjPreClose":857.47,"adrRate":0,"dividendRate":0.00547,"preHourTrading":{"tag":"盘前","latestPrice":866.52,"preClose":857.47,"latestTime":"05:26 EDT","volume":177,"amount":153111.8676,"timestamp":1721640372597},"postHourTrading":{"tag":"盘后","latestPrice":857.1,"preClose":857.47,"latestTime":"19:59 EDT","volume":280453,"amount":240562628.376701,"timestamp":1721433592024},"volumeRatio":1.0147585229876306,"impliedVol":0.421,"impliedVolPercentile":0.98},"requestUrl":"/m/hq/s/LLY/wiki","defaultTab":"wiki","newsList":[{"id":"2453217705","title":"重磅！礼来“减肥针”国内最新获批，司美的最强对手来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453217705","media":"华尔街见闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453217705?lang=zh_cn&edition=full","pubTime":"2024-07-21 09:30","pubTimestamp":1721525428,"startTime":"0","endTime":"0","summary":"宿敌在前，新秀环伺，此次替尔泊肽减重适应证获批只是开始：中国的百亿“减肥针”市场，“双巨头”聚首、国产药逐鹿。","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/167c5259-53fc-47e3-806e-b6ff38af954e.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/167c5259-53fc-47e3-806e-b6ff38af954e.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3720297","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3720297","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0943347566.SGD","IE00BJT1NW94.SGD","LU0466842654.USD","BK4534","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4585","LU0640476718.USD","BK4588","LU0109391861.USD","LU0820561818.USD","LU0114720955.EUR","NVO","LU0385154629.USD","LU1280957306.USD","IE0009355771.USD","LU0672654240.SGD","LU0097036916.USD","LU0198837287.USD","IE00BK4W5M84.HKD","LU0096364046.USD","LU0238689110.USD","LU0689472784.USD","LU0823416689.USD","LU1023059063.AUD","BK4581","LU1035775433.USD","LU0094547139.USD","IE00B2B36J28.USD","IE00BK4W5L77.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU1057294990.SGD","IE00B1BXHZ80.USD","LU0061475181.USD","LU0471298777.SGD","LU1064131342.USD","LU1069344957.HKD","LU1267930730.SGD","LLY","LU0456855351.SGD","LU0708995401.HKD","BK4516","LU0320765059.SGD","LU1712237335.SGD","LU0417517546.SGD","LU0882574139.USD","LU0256863902.USD","LU0820561909.HKD","LU0289739699.SGD","LU1623119135.USD"],"gpt_icon":1},{"id":"2452062894","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452062894","media":"中国基金报","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452062894?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:16","pubTimestamp":1721405811,"startTime":"0","endTime":"0","summary":"国内减重赛道迎来重磅级“选手”。7月19日，记者从国家药品监督管理局获悉，礼来的替尔泊肽注射液长期体重管理适应证获得批准，这是目前首个且是唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407203135777061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407203135777061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LLY","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4532","BK4585","BK4588","LU1093756168.USD","BK4007"],"gpt_icon":1},{"id":"2452405946","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452405946","media":"中国基金报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452405946?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:14","pubTimestamp":1721405689,"startTime":"0","endTime":"0","summary":"中国基金报记者 冯尧国内减重赛道迎来重磅级“选手”。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。如今，随着替尔泊肽加入国内减重赛道，两大巨头将在国内“硬碰硬”。如今，随着礼来的替尔泊肽注射液在国内获批，诺和诺德和礼来两大巨头在中国百亿元级GLP-1市场的正面较量也正式展开。目前，在减重赛道上，国内企业竞争激烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072000172295ddb277&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072000172295ddb277&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","LLY","LU0405327148.USD","600276","BK0196","688166","BK0012","LU2488822045.USD","BK0060","LU2148510915.USD","BK0239","LU0405327494.USD","LU1064131003.USD","LU1328615791.USD","BK0028","603087","BK0188","BK0183"],"gpt_icon":0},{"id":"2452742784","title":"司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452742784","media":"每日经济新闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452742784?lang=zh_cn&edition=full","pubTime":"2024-07-19 22:16","pubTimestamp":1721398617,"startTime":"0","endTime":"0","summary":"7月19日，礼来宣布，穆峰达（替尔泊肽注射液）长期体重管理适应症获得国家药品监督管理局（NMPA）批准。据介绍，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135753480.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135753480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456855351.SGD","IE0002141913.USD","IE00B1BXHZ80.USD","LU0114720955.EUR","LU1804176565.USD","LU0079474960.USD","LU0417517546.SGD","LU0943347566.SGD","BK4534","LU1064131342.USD","LU0238689110.USD","BK4007","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4585","LU0471298694.HKD","NVO","LU0256863902.USD","LU0094547139.USD","LU1023059063.AUD","LU0109391861.USD","LU1267930730.SGD","LU0708995401.HKD","BK4588","LU0320765059.SGD","LU0640476718.USD","BK4581","BK4533","LU0058720904.USD","LU1035775433.USD","LU0061475181.USD","IE00BJLML261.HKD","LU1061106388.HKD","LLY","LU1551013342.USD","LU1551013425.SGD","LU0256863811.USD","LU0122379950.USD","IE00BK4W5M84.HKD","LU0198837287.USD","LU0471298777.SGD","IE00B2B36J28.USD","IE0004445239.USD","GB00BDT5M118.USD","LU0289739699.SGD","IE00BK4W5L77.USD","LU1280957306.USD","LU0882574055.USD","IE00BJT1NW94.SGD","LU0672654240.SGD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2452547353","title":"礼来(LLY)盘前涨超2% 减重适应症获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452547353","media":"金吾财讯","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452547353?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:39","pubTimestamp":1721392760,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)盘前涨超2%，截至发稿，报871美元。消息面上，礼来宣布，穆峰达(替尔泊肽注射液)长期体重管理适应症获得国家药品监督管理局(NMPA)批准。据悉，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。穆峰达可结合并激活GIP受体和GLP-1受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZjBiNzEwNDA3MTQ3NjM4OTQ3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"278009","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU0882574055.USD","IE00BJT1NW94.SGD","LU0466842654.USD","BK4534","IE00BFTCPJ56.SGD","LU0058720904.USD","IE0002141913.USD","BK4585","IE0004445239.USD","LU0109391861.USD","LU0820561818.USD","LU0114720955.EUR","LU0385154629.USD","LU1280957306.USD","IE0009355771.USD","LU0097036916.USD","LU0198837287.USD","GB00BDT5M118.USD","LU0256863811.USD","IE00BJLML261.HKD","LU0096364046.USD","LU0689472784.USD","LU0823416689.USD","LU1023059063.AUD","LU0471298694.HKD","LU1035775433.USD","LU1551013342.USD","LU0094547139.USD","LU0122379950.USD","LU1057294990.SGD","IE00B1BXHZ80.USD","LU0061475181.USD","LU1064131342.USD","LU0079474960.USD","LU1069344957.HKD","IE00BJJMRZ35.SGD","BK4533","LU1804176565.USD","LLY","LU1061106388.HKD","LU0708995401.HKD","LU1551013425.SGD","BK4516","LU1712237335.SGD","LU0882574139.USD","LU0820561909.HKD","BK4007","LU0289739699.SGD","LU1623119135.USD"],"gpt_icon":1},{"id":"2452358420","title":"礼来减肥药在中国获批，将和诺和诺德直接竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2452358420","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452358420?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:30","pubTimestamp":1721392200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月19日，礼来穆峰达长期体重管理适应症获得中国国家药品监督管理局批准。穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽/胰高糖素样肽-1受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。穆峰达可结合并激活GIP受体和GLP-1受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。大量重磅减肥药获批，为目前主要使用诺和诺德的Ozempic的中国患者提供了更多选择。Ozempic仅被批准用于糖尿病治疗。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153452.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"礼来减肥药在中国获批，将和诺和诺德直接竞争","news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1804176565.USD","LU0256863811.USD","BK4516","LLY","BK4534","LU1023059063.AUD","LU0109391861.USD","IE0004445239.USD","LU1093756325.SGD","LU0094547139.USD","LU0385154629.USD","BK4532","LU0708995401.HKD","LU0820561909.HKD","GB00BDT5M118.USD","BK4533","LU0096364046.USD","LU0154236417.USD","LU1057294990.SGD","IE00BK4W5L77.USD","IE00BZ1G4Q59.USD","IE00BJLML261.HKD","LU0079474960.USD","LU1035775433.USD","LU0943347566.SGD","IE00B1BXHZ80.USD","LU1623119135.USD","LU0097036916.USD","LU0058720904.USD","LU0114720955.EUR","LU0122379950.USD","LU1093756168.USD","LU1551013342.USD","LU0289739699.SGD","LU1280957306.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0061475181.USD","LU0417517546.SGD","IE00BK4W5M84.HKD","IE0002141913.USD","LU0471298694.HKD","BK4585","LU0672654240.SGD","NVO","LU0238689110.USD","LU1551013425.SGD","BK4007","LU0882574055.USD"],"gpt_icon":0},{"id":"2452420474","title":"BUZZ-减肥药在中国获批，礼来公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2452420474","media":"Reuters","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452420474?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:29","pubTimestamp":1721392190,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) 7月19日 - ** 礼来 股价盘前上涨2.4%至866.75美元 ** 公司称 (link) 其减肥药替西帕肽已获得中国监管机构的批准 ** 蒂塞帕肽是这家美国制药商的糖尿病药物Mounjaro（也在中国获批）和减肥药物Zepbound的活性成分** 礼来公司和丹麦制药商诺和诺德 在增加减肥药产量的竞争中遥遥领先，预计到2030年代初，减肥药市场将达到约1500亿美元的规模 (link)。** 截至上次收盘，该股今年累计上涨45.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1069344957.HKD","LU1804176565.USD","LU0882574055.USD","LU0943347566.SGD","IE0009355771.USD","LU0061475181.USD","LU0096364046.USD","BK4585","LU0097036916.USD","LU0466842654.USD","LU0640476718.USD","LLY","LU0823416689.USD","LU0882574139.USD","LU1551013342.USD","LU0471298694.HKD","IE00BJJMRZ35.SGD","LU1035775433.USD","BK4516","LU0079474960.USD","LU0122379950.USD","LU0820561909.HKD","LU0385154629.USD","LU1061106388.HKD","LU0114720955.EUR","BK4533","LU0109391861.USD","IE0004445239.USD","IE00B1BXHZ80.USD","NVO","LU0094547139.USD","LU0820561818.USD","IE00BJLML261.HKD","BK4007","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0058720904.USD","LU0708995401.HKD","LU1551013425.SGD","LU0198837287.USD","LU1712237335.SGD","LU0256863811.USD","IE00BJT1NW94.SGD","LU1064131342.USD","GB00BDT5M118.USD","LU1623119135.USD","LU1280957306.USD","BK4534","IE00B4R5TH58.HKD","LU0689472784.USD"],"gpt_icon":1},{"id":"2452478682","title":"礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2452478682","media":"老虎证券","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452478682?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:16","pubTimestamp":1721391360,"startTime":"0","endTime":"0","summary":"【礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争】智通财经APP获悉，7月19日，礼来(LLY.US)穆峰达®(替尔泊肽注射液)长期体重管理适应症获得中国国家药品监督管理局(NMPA)批准。穆峰达®是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192018579f6b9b35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192018579f6b9b35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0094547139.USD","LU0058720904.USD","GB00BDT5M118.USD","LU0882574055.USD","LU0122379950.USD","LU0320765059.SGD","BK4534","IE00B1BXHZ80.USD","BK4532","LU0471298694.HKD","LU1804176565.USD","LU0238689110.USD","LU1035775433.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","IE00BK4W5L77.USD","LU1093756325.SGD","IE00BK4W5M84.HKD","IE0004445239.USD","LU0109391861.USD","IE0002141913.USD","LU1280957306.USD","LU0154236417.USD","LU1023059063.AUD","BK4588","LU0417517546.SGD","LU0256863811.USD","LU0289739699.SGD","LU1551013342.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU1551013425.SGD","BK4533","LU1057294990.SGD","LU1061106388.HKD","IE00BJLML261.HKD","LU0061475181.USD","NVO","LU0114720955.EUR","LU0256863902.USD","LU0672654240.SGD","BK4516","LU0079474960.USD","LU0096364046.USD","BK4581","LU1093756168.USD","LU0097036916.USD","LLY","LU0708995401.HKD","BK4007"],"gpt_icon":1},{"id":"2452478369","title":"国内“减肥神药”赛道再添一员大将 礼来替尔珀肽减重适应症获批｜快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2452478369","media":"华夏时报","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452478369?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:12","pubTimestamp":1721391176,"startTime":"0","endTime":"0","summary":"2024年7月19日，礼来穆峰达?（替尔泊肽注射液）长期体重管理适应症获得国家药品监督管理局（NMPA）批准。穆峰达?是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。礼来官网提到，穆峰达?可结合并激活GIP受体和GLP-1受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135699570.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135699570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0943347566.SGD","LU0882574055.USD","LU0466842654.USD","BK4534","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4585","LU0640476718.USD","BK4588","LU0820561818.USD","LU0114720955.EUR","LU0385154629.USD","IE0009355771.USD","LU0672654240.SGD","LU0097036916.USD","LU0198837287.USD","GB00BDT5M118.USD","IE00BK4W5M84.HKD","LU0256863811.USD","IE00BJLML261.HKD","LU0096364046.USD","LU0238689110.USD","LU0689472784.USD","LU0823416689.USD","LU1551013342.USD","IE00B2B36J28.USD","IE00BK4W5L77.USD","IE00B4R5TH58.HKD","LU0471298777.SGD","LU1064131342.USD","LU0079474960.USD","LU1069344957.HKD","IE00BJJMRZ35.SGD","BK4533","LU1267930730.SGD","LU1804176565.USD","LLY","LU0456855351.SGD","LU1061106388.HKD","LU1551013425.SGD","BK4516","LU0320765059.SGD","LU1712237335.SGD","LU0417517546.SGD","LU0882574139.USD","LU0256863902.USD","LU0820561909.HKD","BK4007","LU0289739699.SGD","LU1623119135.USD"],"gpt_icon":1},{"id":"2452080424","title":"礼来替尔泊肽获批减重新适应症，GLP-1赛道掀王者之争孰胜孰负？","url":"https://stock-news.laohu8.com/highlight/detail?id=2452080424","media":"21世纪经济报道","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452080424?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:25","pubTimestamp":1721388307,"startTime":"0","endTime":"0","summary":"7月19日，国家药品监督管理局（NMPA）官网显示，礼来的葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体双重激动剂Mounjaro（Tirzepatide，替尔泊肽）新适应症获批上市，用于在低热量饮食和增加运动基础上改善成人肥胖或伴有至少一种体重相关合并症的超重患者长期体重管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135667664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135667664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0708995401.HKD","IE00BJT1NW94.SGD","LU0097036916.USD","LU0820561818.USD","LU1023059063.AUD","NVO","GB00BDT5M118.USD","LLY","LU1069344957.HKD","BK4585","LU1804176565.USD","BK4007","IE00B1BXHZ80.USD","LU0122379950.USD","LU1712237335.SGD","LU0096364046.USD","IE00BJJMRZ35.SGD","BK4534","LU0943347566.SGD","IE0009355771.USD","LU1551013342.USD","LU1623119135.USD","LU0256863811.USD","LU1035775433.USD","LU0109391861.USD","LU0079474960.USD","IE0004445239.USD","LU0882574055.USD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","LU0289739699.SGD","LU0823416689.USD","BK4533","LU1061106388.HKD","LU0114720955.EUR","LU1551013425.SGD","BK4516","LU0058720904.USD","LU1280957306.USD","LU0061475181.USD","LU0466842654.USD","LU0385154629.USD","LU0882574139.USD","GLP","IE0002141913.USD","LU0820561909.HKD","LU0689472784.USD","LU0471298694.HKD","LU1057294990.SGD","LU1064131342.USD","LU0094547139.USD"],"gpt_icon":1},{"id":"2452442881","title":"礼来(LLY)的穆峰达(替尔泊肽注射液)减重适应症获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452442881","media":"金吾财讯","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452442881?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:07","pubTimestamp":1721380020,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)宣布，穆峰达(替尔泊肽注射液)长期体重管理适应症获得国家药品监督管理局(NMPA)批准。据悉，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。穆峰达可结合并激活GIP受体和GLP-1受体，通过调节食欲来减少食物摄入、降低体重和减少脂肪量。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGRhYzM3NGFmNjhkZjU2YzllYzhmYTA3NGMxMjcyMzM2MzUzOA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGRhYzM3NGFmNjhkZjU2YzllYzhmYTA3NGMxMjcyMzM2MzUzOA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277988","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","LU1280957306.USD","LU0820561818.USD","LU0096364046.USD","LU0094547139.USD","BK4581","BK4533","IE00BJJMRZ35.SGD","LU0061475181.USD","IE00BK4W5M84.HKD","LU0466842654.USD","BK4534","IE0002141913.USD","IE00BJLML261.HKD","LU0109391861.USD","LU0079474960.USD","LU1035775433.USD","LU0114720955.EUR","BK4588","LLY","IE0004445239.USD","LU0058720904.USD","LU0385154629.USD","LU1804176565.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0256863811.USD","IE00BK4W5L77.USD","LU0823416689.USD","LU1712237335.SGD","LU1551013425.SGD","LU1057294990.SGD","BK4585","LU0122379950.USD","LU1061106388.HKD","LU0097036916.USD","LU0672654240.SGD","LU0289739699.SGD","LU0471298694.HKD","LU0689472784.USD","LU0882574139.USD","LU1023059063.AUD","LU0943347566.SGD","LU1069344957.HKD","GB00BDT5M118.USD","IE00BJT1NW94.SGD","LU0708995401.HKD","LU0882574055.USD","IE00B1BXHZ80.USD","LU1623119135.USD"],"gpt_icon":1},{"id":"2452441340","title":"礼来公司的减肥药替西帕肽在中国获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452441340","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452441340?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:40","pubTimestamp":1721378400,"startTime":"0","endTime":"0","summary":"诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 。礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0672654240.SGD","LU1804176565.USD","LU1551013342.USD","IE00BFTCPJ56.SGD","LU0882574139.USD","LU1712237335.SGD","BK4533","LU0114720955.EUR","LU0385154629.USD","LU0689472784.USD","LU0097036916.USD","LU1061106388.HKD","IE00BK4W5M84.HKD","IE0004445239.USD","LU0943347566.SGD","IE0009355771.USD","BK4588","BK4534","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0058720904.USD","LU0079474960.USD","LU0289739699.SGD","LU1035775433.USD","LU1057294990.SGD","LU0096364046.USD","LU1069344957.HKD","LU1551013425.SGD","LU1280957306.USD","LU1023059063.AUD","LU0094547139.USD","LU0820561818.USD","GB00BDT5M118.USD","LU0882574055.USD","LLY","LU0466842654.USD","IE0002141913.USD","BK4581","IE00BJLML261.HKD","LU0109391861.USD","LU0122379950.USD","LU0708995401.HKD","LU0820561909.HKD","BK4007","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","LU1623119135.USD","LU0061475181.USD","LU0256863811.USD","NVO","LU0471298694.HKD"],"gpt_icon":1},{"id":"2452460394","title":"最高减重20%！礼来替尔泊肽减重适应证在国内获批，诺和诺德迎强劲对手","url":"https://stock-news.laohu8.com/highlight/detail?id=2452460394","media":"澎湃新闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452460394?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:18","pubTimestamp":1721377080,"startTime":"0","endTime":"0","summary":"今年5月21日，礼来中国宣布，替尔泊肽在中国获批用于适应证是二型糖尿病。如今，随着替尔泊肽减重适应证在国内获批，诺和诺德和礼来在中国百亿GLP-1市场的正面较量也正式展开。减重效果方面，诺和诺德此前表示，司美格鲁肽能够实现平均17%的体重降幅。具体来看，2022年5月，替尔泊肽糖尿病适应证Mounjaro首次获美国食品药品监督管理局批准上市，2022年该药为礼来贡献了4.83亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191619049f6a68f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191619049f6a68f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GB00BDT5M118.USD","LU0823416689.USD","LU0466842654.USD","LU0122379950.USD","LU1551013425.SGD","IE0009355771.USD","IE0004445239.USD","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BJJMRZ35.SGD","LU0820561909.HKD","LU0385154629.USD","LU0256863902.USD","IE00BK4W5M84.HKD","LU1267930730.SGD","LU0061475181.USD","LU1061106388.HKD","LU1035775433.USD","LU0672654240.SGD","LU1551013342.USD","LU0097036916.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0943347566.SGD","LU1064131342.USD","LU0256863811.USD","LU1057294990.SGD","BK4532","LU0471298694.HKD","LU0094547139.USD","LU0154236417.USD","LU0456855351.SGD","LU0079474960.USD","LU0417517546.SGD","LU1804176565.USD","LU0689472784.USD","LU1023059063.AUD","NVO","LU0109391861.USD","BK4581","IE00B4R5TH58.HKD","BK4007","LU1069344957.HKD","LU0198837287.USD","LLY","LU0058720904.USD","LU0114720955.EUR","BK4585","LU1093756168.USD","LU0096364046.USD"],"gpt_icon":1},{"id":"1189846922","title":"昨夜今晨 | 道指结束六连涨！特朗普即将发表“新黄金时代”演讲；巴菲特旗下公司盘后涨近48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189846922","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1189846922?lang=zh_cn&edition=full","pubTime":"2024-07-19 08:10","pubTimestamp":1721347834,"startTime":"0","endTime":"0","summary":"摘要：道指跌超1%结束六连涨，$英伟达$涨近3%!上架“便宜又强悍”的GPT-4o mini模型美媒：拜登在逐渐接受其可能败选及退选的可能海外市场美股收盘 | 道指跌超1%结束六连涨，英伟达涨近3%!共和党全国委员会介绍称，周四大会的关注重点是“特朗普如何为美国开启一个新黄金时代”。减肥药“双雄”遭遇连日股价下跌，礼来下跌6.26%，$诺和诺德$下跌4.01%。此次抛售潮恰逢竞争对手罗氏公布口服减肥药的初期积极试验结果。","market":"us","thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".DJI","NVDA","LU0077335932.USD","BK4533","LU0094547139.USD","LU1551013342.USD","LU1035775433.USD","LU1551013425.SGD","BK4532","IE00BJJMRX11.SGD","IE0009356076.USD","BK4567","IE0004091025.USD","LU1023059063.AUD","BK4534","LU0079474960.USD","LU1623119135.USD","LLY","LU0417517546.SGD"],"gpt_icon":1},{"id":"2452453285","title":"标普500指数扩大跌幅，日内下跌1%。医药板块领跌，礼来（LLY）跌6.2%，诺华（NVS）与雅培（ABT）各跌逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452453285","media":"华尔街见闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452453285?lang=zh_cn&edition=full","pubTime":"2024-07-19 02:58","pubTimestamp":1721329084,"startTime":"0","endTime":"0","summary":"更多消息，持续更新中","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/d0/24/94/-1-2-.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3720109","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3720109","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["OEX","ABT","LU0640476718.USD","SPXU","BK4534","BK4082","LU0456855351.SGD","BK4588","LU0234572021.USD","LU0266013472.USD","LU0320765059.SGD","LU0256863902.USD","LU1064131342.USD","09939","BK1574","BK4581","IE00BK4W5L77.USD","SDS","SH","IE00BK4W5M84.HKD","LLY","UPRO","LU0238689110.USD","LU0471298777.SGD","LU1057294990.SGD","BK4532","LU0289739699.SGD","NVS","LU2468319806.SGD","BK4504","IE00B4R5TH58.HKD","LU0094547139.USD",".SPX","SPY","LU2237957811.SGD","BK4592","OEF","SGXZ23171101.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU0417517546.SGD","SG9999004303.SGD","SSO","ESmain","LU0198837287.USD","LU1267930730.SGD","IVV","LU2237957902.USD","SG9999002224.SGD","LU0672654240.SGD"],"gpt_icon":1},{"id":"2452431502","title":"BUZZ-礼来股价创逾一个月新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2452431502","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452431502?lang=zh_cn&edition=full","pubTime":"2024-07-19 00:21","pubTimestamp":1721319687,"startTime":"0","endTime":"0","summary":" 7月18日 - ** 礼来 股价下跌7.51%，创下837美元的一个多月新低，将连续第三天下跌。** LLY 周三收盘下跌 3.8%** 在一项为期 12 周的中期研究中，该公司的口服药物 orforglipron 可使患者体重减轻约 6% 至 7%；后期数据预计将于 2025 年 4 月公布** 我认为罗氏公司的消息造成了一些压力，尤其是礼来公司近期涨幅如此之大--晨星分析师 Damien Conover** Conover 认为礼来估值过高，市场没有充分认识到礼来的肥胖症药物组合在未来几年可能面临的竞争压力。** LLY 股价今年以来上涨了 44","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765059.SGD","BUZZ","LU0114720955.EUR","LU0198837287.USD","IE0004445239.USD","GB00BDT5M118.USD","IE0009355771.USD","LU0471298777.SGD","LU1267930730.SGD","LU0672654240.SGD","BK4588","IE00BK4W5M84.HKD","BK4585","IE00B2B36J28.USD","LU0820561909.HKD","LU0097036916.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU0466842654.USD","LU1551013342.USD","LU0385154629.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU1712237335.SGD","LU0689472784.USD","LU1804176565.USD","BK4581","BK4007","LU0943347566.SGD","IE0002141913.USD","LU0238689110.USD","LU0256863902.USD","LU0882574139.USD","IE00B4R5TH58.HKD","LU1551013425.SGD","LU1064131342.USD","LU0640476718.USD","IE00BJLML261.HKD","BK4516","LU0882574055.USD","IE00BK4W5L77.USD","LU1061106388.HKD","LU0823416689.USD","LU1069344957.HKD","LU0256863811.USD","LU0820561818.USD","LU0079474960.USD","LU1623119135.USD","LLY","LU0417517546.SGD"],"gpt_icon":1},{"id":"2452176435","title":"礼来美股走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2452176435","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452176435?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:23","pubTimestamp":1721316192,"startTime":"0","endTime":"0","summary":"礼来美股下跌超5%，至一个月低点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718232312aefa59e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718232312aefa59e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765059.SGD","LU0114720955.EUR","LU0058720904.USD","LU1280957306.USD","IE00BJT1NW94.SGD","IE0004445239.USD","LU0471298694.HKD","GB00BDT5M118.USD","IE0009355771.USD","LU0672654240.SGD","IE00BK4W5M84.HKD","BK4533","LU0820561909.HKD","LU0094547139.USD","LU0097036916.USD","LU0122379950.USD","LU1551013342.USD","LI","LU0385154629.USD","LU0708995401.HKD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU1712237335.SGD","LU1057294990.SGD","LU0689472784.USD","LU1804176565.USD","BK4581","BK4007","LU0943347566.SGD","IE0002141913.USD","LU0238689110.USD","LU0256863902.USD","LU1035775433.USD","LU0109391861.USD","LU1551013425.SGD","IE00BJLML261.HKD","BK4516","LU0882574055.USD","IE00BK4W5L77.USD","LU1061106388.HKD","LU1023059063.AUD","LU1069344957.HKD","LU0061475181.USD","LU0256863811.USD","LU0289739699.SGD","BK4534","LU0079474960.USD","LU1623119135.USD","LLY","LU0417517546.SGD","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"1110119848","title":"诺和诺德、礼来均跌超5%！“减肥药双雄”连续两个交易日大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1110119848","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1110119848?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:12","pubTimestamp":1721315557,"startTime":"0","endTime":"0","summary":"7月18日，$诺和诺德(NVO)$、$礼来(LLY)$均跌超5%，“减肥药双雄”连续两个交易日大跌。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0466842654.USD","LU0471298694.HKD","LLY","LU0122379950.USD","LU1551013425.SGD","LU0096364046.USD","LU0882574055.USD","BK4532","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","LU1035775433.USD","BK4585","LU0689472784.USD","LU1064131342.USD","NVO","IE00BK4W5M84.HKD","LU1061106388.HKD","NVO.AU","IE00BKVL7J92.USD","LU0097036916.USD"],"gpt_icon":0},{"id":"2452484222","title":"礼来下跌1.3%，报893.86美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452484222","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452484222?lang=zh_cn&edition=full","pubTime":"2024-07-18 21:45","pubTimestamp":1721310326,"startTime":"0","endTime":"0","summary":"7月18日，礼来(LLY)盘中下跌1.3%，截至21:45，报893.86美元/股，成交3.07亿美元。财务数据显示，截至2024年03月31日，礼来收入总额87.68亿美元，同比增长25.98%；归母净利润22.43亿美元，同比增长66.77%。大事提醒：7月15日，礼来获Cantor Fitzgerald重申评级Overweight，目标价885美元。8月8日，礼来将于(美东)盘前披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/18214541660893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0672654240.SGD","LU1804176565.USD","LU1551013342.USD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","BK4533","LU0114720955.EUR","LU0238689110.USD","LU0385154629.USD","LU0097036916.USD","LU0689472784.USD","IE00BK4W5M84.HKD","IE0004445239.USD","LU1061106388.HKD","LU0943347566.SGD","LU1064131342.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU1069344957.HKD","LU1267930730.SGD","LU1035775433.USD","LU1057294990.SGD","LU0096364046.USD","LU0823416689.USD","LU1280957306.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU0094547139.USD","LU0198837287.USD","LU0820561818.USD","GB00BDT5M118.USD","LU0640476718.USD","LLY","IE0002141913.USD","BK4581","IE00BJLML261.HKD","LU0109391861.USD","LU0122379950.USD","LU0708995401.HKD","LU0820561909.HKD","BK4007","BK4516","IE00BK4W5L77.USD","LU0320765059.SGD","LU0061475181.USD","LU0471298694.HKD"],"gpt_icon":1},{"id":"2452484477","title":"礼来跌0.87% 股价跌破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2452484477","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452484477?lang=zh_cn&edition=full","pubTime":"2024-07-18 21:43","pubTimestamp":1721310233,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日21时43分，礼来股票出现异动，股价快速下跌0.87%。截至发稿，该股报897.74美元/股，成交量25.0829万股，换手率0.03%，振幅1.06%。最近的财报数据显示，该股实现营业收入87.68亿美元，净利润22.43亿美元，每股收益2.49美元，毛利70.95亿美元，市盈率132.63倍。礼来股票所在的制药行业中，整体跌幅为0.26%。礼来制药公司的主要产品包括治疗癌症的 Verzenio；用于治疗糖尿病的 Mounjaro、Zepbound、Jardiance、Trulicity、Humalog 和 Humulin；以及免疫学方面的 Taltz 和 Olumiant。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407182143539681e14a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407182143539681e14a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GB00BDT5M118.USD","LU0823416689.USD","LU0466842654.USD","LU0122379950.USD","LU0320765059.SGD","LU1551013425.SGD","IE0009355771.USD","IE0004445239.USD","IE00BJJMRZ35.SGD","LU0820561909.HKD","LU0385154629.USD","LU0256863902.USD","LU1267930730.SGD","BK4534","LU1061106388.HKD","LU0238689110.USD","LU1551013342.USD","BK4588","LU0097036916.USD","LU0882574139.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0943347566.SGD","LU1064131342.USD","LU0640476718.USD","LU0471298777.SGD","LU0096364046.USD","LU0256863811.USD","LU0471298694.HKD","LU0456855351.SGD","LU1804176565.USD","LU0079474960.USD","IE0002141913.USD","LU0689472784.USD","LU0882574055.USD","LU1712237335.SGD","BK4581","BK4533","IE00B4R5TH58.HKD","IE00BJLML261.HKD","LU0820561818.USD","BK4007","LU1069344957.HKD","LU0198837287.USD","LLY","LU0058720904.USD","LU0114720955.EUR","LU1623119135.USD","BK4585","BK4516"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":-0.0959},{"period":"1month","weight":-0.0381},{"period":"3month","weight":0.1806},{"period":"6month","weight":0.3641},{"period":"1year","weight":0.8487},{"period":"ytd","weight":0.471}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.555556,"avgChangeRate":0.018718},{"month":5,"riseRate":0.422222,"avgChangeRate":0.014916},{"month":6,"riseRate":0.6,"avgChangeRate":0.02296},{"month":7,"riseRate":0.555556,"avgChangeRate":0.00096},{"month":8,"riseRate":0.409091,"avgChangeRate":0.00001},{"month":9,"riseRate":0.454545,"avgChangeRate":0.003204},{"month":10,"riseRate":0.590909,"avgChangeRate":0.014439},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}